Literature DB >> 9840719

Bcl-2 expression correlates with apoptosis induction but not loss of clonogenic survival in small cell lung cancer cell lines treated with etoposide.

C Breton1, M D Story, R E Meyn.   

Abstract

The influence of bcl-2 oncogene expression on etoposide-induced apoptosis and clonogenic survival was investigated in five small cell lung cancer (SCLC) cell lines, three of which were bcl-2-expressing and two of which were non-bcl-2-expressing. The bcl-2-expressing lines displayed a lower apoptosis propensity than the non-bcl-2-expressing lines. When bcl-2-expressing cells were incubated in cystine/ methionine-free (CMF) medium, etoposide-induced apoptosis was restored to levels comparable to those seen in non-bcl-2-expressing lines. However, the endpoint of clonogenic survival after drug treatment did not display any consistent pattern that correlated with bcl-2 status. In addition, treatment of the two bcl-2-expressing cell lines with etoposide in CMF medium did not modify their clonogenic survival curves compared to treatment in regular medium. These results are consistent with the idea that bcl-2 expression modulates etoposide-induced apoptosis but not clonogenic survival.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9840719     DOI: 10.1097/00001813-199810000-00002

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  2 in total

1.  Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors.

Authors:  Leena Gandhi; D Ross Camidge; Moacyr Ribeiro de Oliveira; Philip Bonomi; David Gandara; Divis Khaira; Christine L Hann; Evelyn M McKeegan; Elizabeth Litvinovich; Philip M Hemken; Caroline Dive; Sari H Enschede; Cathy Nolan; Yi-Lin Chiu; Todd Busman; Hao Xiong; Andrew P Krivoshik; Rod Humerickhouse; Geoffrey I Shapiro; Charles M Rudin
Journal:  J Clin Oncol       Date:  2011-01-31       Impact factor: 44.544

2.  Resistance to BH3 mimetic S1 in SCLC cells that up-regulate and phosphorylate Bcl-2 through ERK1/2.

Authors:  Yubo Liu; Zhichao Zhang; Ting Song; Furong Liang; Mingzhou Xie; Hongkun Sheng
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.